Table 5 Treatment-Emergent Cardiovascular Adverse Events in Patients with Cardiovascular Risk Factors at Baseline
|  | Eptinezumab 100 mg | Eptinezumab 300 mg | Eptinezumab 1000 mg | Placebo |
|---|---|---|---|---|
Patients with at least 1 cardiovascular risk factor, n (%) | N = 350 | N = 316 | N = 41 | N = 382 |
Any TEAE | 196 (56.0) | 187 (59.2) | 22 (53.7) | 220 (57.6) |
Cardiac or Vascular TEAEs | 13 (3.7) | 14 (4.4) | 4 (9.8) | 19 (5.0) |
 Increased blood pressure | 5 (1.4) | 3 (0.9) | 0 | 2 (0.5) |
 Hypertension | 2 (0.6) | 1 (0.3) | 0 | 5 (1.3) |
 Hot flush | 0 | 3 (0.9) | 0 | 0 |
 Palpitations | 1 (0.3) | 1 (0.3) | 0 | 3 (0.8) |
 Syncope | 2 (0.6) | 2 (0.6) | 0 | 3 (0.8) |
 Tachycardia | 0 | 2 (0.6) | 0 | 1 (0.3) |
 Chest pain | 0 | 0 | 1 (2.4) | 1 (0.3) |
 ECG QT prolongation | 0 | 0 | 2 (4.9) | 1 (0.3) |
 Flushing | 0 | 1 (0.3) | 0 | 1 (0.3) |
 Sinus tachycardia | 1 (0.3) | 0 | 0 | 0 |
 Increased systolic blood pressure | 1 (0.3) | 0 | 0 | 0 |
 Abnormal ECG Q wave | 0 | 0 | 1 (2.4) | 0 |
 Increased heart rate | 0 | 1 (0.3) | 0 | 0 |
 Hypotension | 1 (0.3) | 0 | 0 | 0 |
 Atrial fibrillation | 0 | 0 | 0 | 1 (0.3) |
 Prehypertension | 0 | 0 | 0 | 1 (0.3) |
Patients with at least 2 cardiovascular risk factors, n (%) | N = 97 | N = 83 | N = 7 | N = 112 |
Any TEAE | 54 (55.7) | 51 (61.4) | 4 (57.1) | 69 (61.6) |
Cardiac or Vascular TEAEs | 8 (8.2) | 4 (4.8) | 0 | 8 (7.1) |
 Increased blood pressure | 2 (2.1) | 1 (1.2) | 0 | 1 (0.9) |
 Hypertension | 2 (2.1) | 1 (1.2) | 0 | 4 (3.6) |
 Syncope | 2 (2.1) | 1 (1.2) | 0 | 2 (1.8) |
 Palpitations | 1 (1.0) | 0 | 0 | 0 |
 Hot flush | 0 | 1 (1.2) | 0 | 0 |
 Sinus tachycardia | 1 (1.0) | 0 | 0 | 0 |
 Atrial fibrillation | 0 | 0 | 0 | 1 (0.9) |